PMV Pharmaceuticals (PMVP) Current Leases (2021 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Current Leases came in at $293000.0 in Q1 2026, down 19.51% YoY from $364000.0 in Q1 2025, and down 27.3% on a QoQ basis from $403000.0 in Q4 2025.
PMV Pharmaceuticals (PMVP) Current Leases (2021 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 6 years of Current Leases data on file, last reported at $293000.0 in Q1 2026.
- Quarterly Current Leases fell 19.51% year-over-year to $293000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293000.0 (down 19.51% YoY) and the FY2025 annual result came in at $403000.0, up 14.49% from the prior year.
- Current Leases slipped to $293000.0 in Q1 2026, from $403000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.2 million in Q3 2024 to a low of $18000.0 in Q2 2023.
- A 5-year average of $510437.5 and a median of $386500.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases sank 95.3% — and 2024, when it jumped 6294.44%.
- Tracing PMVP's Current Leases over 5 years: stood at $528000.0 in 2022, then surged by 61.36% to $852000.0 in 2023, then sank by 58.69% to $352000.0 in 2024, then advanced by 14.49% to $403000.0 in 2025, then retreated by 27.3% to $293000.0 in 2026.
- The last three Current Leases figures came in at $293000.0 (Q1 2026), $403000.0 (Q4 2025), and $390000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 217,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293,000.00 |
| Dec 31, 2025 | 403,000.00 |
| Sep 30, 2025 | 390,000.00 |
| Jun 30, 2025 | 377,000.00 |
| Mar 31, 2025 | 364,000.00 |
| Dec 31, 2024 | 352,000.00 |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 880,000.00 |
| Dec 31, 2023 | 852,000.00 |
| Jun 30, 2023 | 18,000.00 |
| Mar 31, 2023 | 281,000.00 |
| Dec 31, 2022 | 528,000.00 |
| Sep 30, 2022 | 394,000.00 |
| Jun 30, 2022 | 383,000.00 |
| Mar 31, 2022 | 258,000.00 |
| Dec 31, 2021 | 403,000.00 |
| Sep 30, 2021 | 545,000.00 |
| Jun 30, 2021 | 677,000.00 |
| Mar 31, 2021 | 666,000.00 |